4.7 Review

The search for an HIV cure: tackling latent infection

期刊

LANCET INFECTIOUS DISEASES
卷 13, 期 7, 页码 614-621

出版社

ELSEVIER SCI LTD
DOI: 10.1016/S1473-3099(13)70043-4

关键词

-

资金

  1. Gilead
  2. Merck
  3. Janssen
  4. Abbott
  5. Pfizer
  6. ViiV Healthcare

向作者/读者索取更多资源

Strategies to eliminate infectious HIV that persists despite present treatments and with the potential to cure HIV infection are of great interest. One patient seems to have been cured of HIV infection after receiving a bone marrow transplant with cells resistant to the virus, although this strategy is not viable for large numbers of infected people. Several clinical trials are underway in which drugs are being used to activate cells that harbour latent HIV. In a recent study, investigators showed that activation of latent HIV infection in patients on antiretroviral therapy could be achieved with a single dose of vorinostat, a licensed anticancer drug that inhibits histone deacetylase. Although far from a cure, such studies provide some guidance towards the logical next steps for research. Clinical studies that use a longer duration of drug dosing, alternative agents, combination approaches, gene therapy, and immune-modulation approaches are all underway.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据